DK3564257T3 - Mutante fragmenter af ospa og fremgangsmåder og anvendelser relateret dertil - Google Patents

Mutante fragmenter af ospa og fremgangsmåder og anvendelser relateret dertil

Info

Publication number
DK3564257T3
DK3564257T3 DK19177679.8T DK19177679T DK3564257T3 DK 3564257 T3 DK3564257 T3 DK 3564257T3 DK 19177679 T DK19177679 T DK 19177679T DK 3564257 T3 DK3564257 T3 DK 3564257T3
Authority
DK
Denmark
Prior art keywords
ospa
methods
uses related
mutant fragments
mutant
Prior art date
Application number
DK19177679.8T
Other languages
English (en)
Inventor
Urban Lundberg
Wolfgang Schüler
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Application granted granted Critical
Publication of DK3564257T3 publication Critical patent/DK3564257T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1207—Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DK19177679.8T 2014-01-09 2015-01-09 Mutante fragmenter af ospa og fremgangsmåder og anvendelser relateret dertil DK3564257T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14150682 2014-01-09
EP15703228.5A EP3092246B1 (en) 2014-01-09 2015-01-09 Mutant fragments of ospa and methods and uses relating thereto

Publications (1)

Publication Number Publication Date
DK3564257T3 true DK3564257T3 (da) 2025-09-15

Family

ID=49917594

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19177679.8T DK3564257T3 (da) 2014-01-09 2015-01-09 Mutante fragmenter af ospa og fremgangsmåder og anvendelser relateret dertil
DK15703228.5T DK3092246T3 (da) 2014-01-09 2015-01-09 Muterede fragmenter af ospa og fremgangsmåder og anvendelser i tilknytning dertil

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15703228.5T DK3092246T3 (da) 2014-01-09 2015-01-09 Muterede fragmenter af ospa og fremgangsmåder og anvendelser i tilknytning dertil

Country Status (26)

Country Link
US (5) US9975927B2 (da)
EP (2) EP3564257B1 (da)
JP (1) JP6505110B2 (da)
KR (1) KR102460165B1 (da)
CN (1) CN105980398B (da)
AU (1) AU2015205520B2 (da)
BR (2) BR122023024315A2 (da)
CA (1) CA2931110A1 (da)
CY (1) CY1121734T1 (da)
DK (2) DK3564257T3 (da)
EA (1) EA034554B1 (da)
ES (2) ES2740985T3 (da)
FI (1) FI3564257T3 (da)
HR (2) HRP20250954T1 (da)
HU (2) HUE072712T2 (da)
LT (1) LT3092246T (da)
MX (1) MX369195B (da)
NZ (1) NZ721015A (da)
PL (2) PL3092246T3 (da)
PT (2) PT3092246T (da)
RS (1) RS59075B1 (da)
SI (2) SI3564257T1 (da)
SM (1) SMT201900383T1 (da)
TR (1) TR201910117T4 (da)
WO (1) WO2015104396A1 (da)
ZA (1) ZA201602690B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986704B2 (en) * 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
MX369195B (es) * 2014-01-09 2019-10-31 Valneva Austria Gmbh Fragmentos mutantes de ospa y métodos y usos relacionados con estos.
WO2018189372A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
IL297166A (en) * 2020-04-09 2022-12-01 Valneva Austria Gmbh Compositions comprising three ospa fusion proteins for medical use
US20240026412A1 (en) * 2020-04-09 2024-01-25 Valneva Austria Gmbh Improved methods of producing a lipidated protein
EP4262860A4 (en) 2020-12-17 2025-11-12 Idexx Lab Inc DETECTION AND TREATMENT OF ROCKY MOUNTAIN SPRINKLE FEVER
CA3250015A1 (en) 2022-04-25 2023-11-02 Pfizer Inc. COMPOSITIONS AND METHODS FOR TRIGGERING IMMUNE PROTECTION AGAINST LYME DISEASE
WO2024050512A2 (en) * 2022-09-02 2024-03-07 The Medical College Of Wisconsin, Inc. Use of immunogenic t cell epitopes for lyme disease vaccination and diagnosis
EP4743110A1 (en) 2023-07-10 2026-05-20 Dynavax Technologies Corporation Lyme disease vaccines containing an adjuvant and Borrelia outer surface protein A and C antigens
JP2026525284A (ja) 2023-07-10 2026-07-29 ダイナヴァックス テクノロジーズ コーポレイション アジュバントおよびｂｏｒｒｅｌｉａ細胞表層タンパク質ａ抗原を含むライム病ワクチン
WO2025212893A1 (en) * 2024-04-04 2025-10-09 The Medical College Of Wisconsin, Inc. Compositions and methods for treating and/or preventing lyme disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
EP1311540B1 (en) 2000-08-18 2007-12-19 Research Foundation Of State University Of New York Altered ospa of borrelia burgdorferi
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
EP2289906A1 (en) * 2006-09-15 2011-03-02 Intercell AG Borrelia antigens
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8623375B2 (en) * 2010-05-14 2014-01-07 Baxter International Inc. Chimeric OspA genes, proteins, and methods of use thereof
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
MX369195B (es) * 2014-01-09 2019-10-31 Valneva Austria Gmbh Fragmentos mutantes de ospa y métodos y usos relacionados con estos.
CZ2014320A3 (cs) 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
WO2018189372A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto

Also Published As

Publication number Publication date
CN105980398A (zh) 2016-09-28
US20180362593A1 (en) 2018-12-20
PL3564257T3 (pl) 2025-11-17
HRP20191086T1 (hr) 2019-11-01
MX369195B (es) 2019-10-31
JP6505110B2 (ja) 2019-04-24
CA2931110A1 (en) 2015-07-16
FI3564257T3 (fi) 2025-09-18
BR112016015678B1 (pt) 2024-02-06
US20210054032A1 (en) 2021-02-25
SMT201900383T1 (it) 2019-09-09
ES3041237T3 (en) 2025-11-11
MX2016008989A (es) 2016-10-04
US11572392B2 (en) 2023-02-07
JP2017503792A (ja) 2017-02-02
DK3092246T3 (da) 2019-07-15
KR20160102993A (ko) 2016-08-31
US9975927B2 (en) 2018-05-22
PL3092246T3 (pl) 2019-09-30
AU2015205520B2 (en) 2017-06-29
BR112016015678A2 (pt) 2017-10-03
PT3564257T (pt) 2025-09-08
NZ721015A (en) 2017-09-29
HRP20250954T1 (hr) 2025-10-10
US20230322869A1 (en) 2023-10-12
EP3564257A1 (en) 2019-11-06
ZA201602690B (en) 2017-09-27
CY1121734T1 (el) 2020-07-31
US20160333056A1 (en) 2016-11-17
KR102460165B1 (ko) 2022-10-28
EA034554B1 (ru) 2020-02-19
TR201910117T4 (tr) 2019-07-22
PT3092246T (pt) 2019-07-19
EA201691095A1 (ru) 2017-03-31
WO2015104396A1 (en) 2015-07-16
SI3564257T1 (sl) 2025-12-31
RS59075B1 (sr) 2019-09-30
CN105980398B (zh) 2019-11-26
AU2015205520A1 (en) 2016-06-30
EP3092246A1 (en) 2016-11-16
US20260070950A1 (en) 2026-03-12
HUE072712T2 (hu) 2025-12-28
BR122023024315A2 (pt) 2023-12-26
SI3092246T1 (sl) 2019-08-30
EP3564257B1 (en) 2025-06-18
HUE043779T2 (hu) 2019-09-30
ES2740985T3 (es) 2020-02-07
LT3092246T (lt) 2019-07-10
EP3092246B1 (en) 2019-06-05
US10766931B2 (en) 2020-09-08

Similar Documents

Publication Publication Date Title
DK3183880T3 (da) Samling af intra-blok-kopi og interprædiktion
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
IL253463A0 (en) Binding-triggered transcriptional switches and methods of use thereof
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
IL251988A0 (en) Glycan-interacting compounds and methods of use
DK3313882T3 (da) Anti-VISTA antistoffer og fragmenter
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3212189T3 (da) Substituerede chromaner og fremgangsmåde til anvendelse deraf
DK3725357T3 (da) Opholdsstrukturer og relaterede fremgangsmåder
DK2949365T3 (da) Gåtræningsapparat og gåtræningsfremgangsmåde deraf
DK3210977T3 (da) Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3116533T3 (da) Deletion af dystrophingenexon under anvendelse af genmanipulerede nukleaser
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3394065T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse
HUE072712T2 (hu) OspA mutáns fragmentumai és azokhoz kapcsolódó eljárások és alkalmazások
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3194564T3 (da) Trichodermasammensætninger og anvendelsesfremgangsmåder
DK3142664T3 (da) Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
BR112016024803A2 (pt) suportes abrasivos e métodos de sua formação
DK3212776T3 (da) Sammensætninger og fremgangsmåder i forbindelse med beta-glucosidase
DK3595395T3 (da) Brugerudstyr og fremgangsmåde
DK3220937T3 (da) Pneumolysinmutanter og fremgangsmåder til anvendelse deraf